Multimedia

Figure 5

Restricted access
Clinical Evaluation of a Paclitaxel-Eluting Balloon for Treatment of Femoropopliteal Arterial Disease
Figure 1

Restricted access
A Freestyle Problem
Figure2

Restricted access
A Freestyle Problem
Figure3

Restricted access
A Freestyle Problem
View table

Table 1

Restricted access
Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
View table

Table 2

Restricted access
Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
Figure 1

Restricted access
Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
Figure 2

Restricted access
Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
View table

Table 3

Restricted access
Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
View table

Table 4

Restricted access
Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter
Figure 1

Restricted access
Iatrogenic Subclavian Artery Pseudoaneurysm Complicating a Transradial Percutaneous Coronary Intervention
View table

Table 1

Restricted access
Progress Toward Doing the Right Thing
View table

Table 1

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
View table

Table 2

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
Figure 1

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
Figure 2

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
Figure 3

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
View table

Table 3

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
View table

Table 4

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes
Figure 4

Restricted access
Long-Term Comparison of Everolimus- and Sirolimus-Eluting Stents in Patients With Acute Coronary Syndromes

Pages

Advertisement